Enzyme-linked immunosorbent assay for the detection of Epstein-Barr Virus-Induced Antigens and antibodies

1983 ◽  
Vol 63 (2) ◽  
pp. 171-185 ◽  
Author(s):  
Lars Sternås ◽  
Janos Luka ◽  
Bengt Kallin ◽  
Anders Rosén ◽  
Werner Henle ◽  
...  
1982 ◽  
Vol 146 (6) ◽  
pp. 734-740 ◽  
Author(s):  
Ralph F. Hopkins ◽  
Tracy J. Witmer ◽  
Russell H. Neubauer ◽  
Harvey Rabin

1998 ◽  
Vol 36 (11) ◽  
pp. 3359-3361 ◽  
Author(s):  
K. H. Chan ◽  
R. X. Luo ◽  
H. L. Chen ◽  
M. H. Ng ◽  
W. H. Seto ◽  
...  

A new immunoglobulin M (IgM) enzyme-linked immunosorbent assay (ELISA) based on the recombinant Epstein-Barr virus (EBV) matrix protein was developed. Compared to indirect immunofluorescence for the detection of IgM antibody to the EBV capsid antigen on clinical specimens, the sensitivity and specificity of the new IgM ELISA were 96 and 96%, respectively.


1999 ◽  
Vol 37 (7) ◽  
pp. 2366-2368 ◽  
Author(s):  
D. Tranchand-Bunel ◽  
H. Gras-Masse ◽  
B. Bourez ◽  
L. Dedecker ◽  
C. Auriault

An immunoglobulin M (IgM) enzyme-linked immunosorbent assay (ELISA) was developed by using a 24-amino-acid peptide of the 18-kDa Epstein-Barr virus (EBV) viral capsid antigen (VCAp18). IgM detection was increased by 23% by using this antigen. Detection of IgM antibodies to the EBV proteins in the new ELISA was 100% specific and 95% sensitive.


2008 ◽  
Vol 15 (11) ◽  
pp. 1684-1688 ◽  
Author(s):  
Ai-Di Gu ◽  
Hao-Yuan Mo ◽  
Yan-Bo Xie ◽  
Rou-Jun Peng ◽  
Jin-Xin Bei ◽  
...  

ABSTRACT Assessment of antibody responses to Epstein-Barr virus (EBV) antigens has been used to assist in nasopharyngeal carcinoma (NPC) diagnosis by several methods. In this study, we evaluated an in-house Luminex multianalyte profiling (xMAP) technology and commercial enzyme-linked immunosorbent assay (ELISA) kits for serological examination of EBV-specific antibody responses in 135 NPC patients and 130 healthy controls. Four EBV biomarkers were measured: immunoglobulin A (IgA) against viral capsid antigen (VCA), EBV nuclear antigen 1 (EBNA1), diffused early antigen (EA-D), and IgG against EA-D. The sensitivities and specificities of the four markers ranged between 71.5 and 90% for xMAP assays and 80 and 92% for ELISA. Logistic regression analysis revealed that the combined markers in the xMAP assay had overall sensitivity and specificity values of 82% and 92%, respectively. The correlation coefficient (r) values for the xMAP assay and ELISA were lowest for IgA-VCA (0.468) and highest for IgA-EBNA1 (0.846); for IgA-EA-D and IgG-EA-D, the r values were 0.719 and 0.798, respectively. The concordances of the two methods for NPC discrimination were good (79 to 88%). Our results suggest that both the xMAP assay and ELISA are satisfactory for EBV antibody evaluation when multiple antigens are included.


1984 ◽  
Vol 67 (2) ◽  
pp. 225-233 ◽  
Author(s):  
Gottfried Dölken ◽  
Ulrike Weitzmann ◽  
Carola Boldt ◽  
Michael Bitzer ◽  
Wolfram Brugger ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document